Skip to main content
. 2022 Sep 15;10(5):e003036. doi: 10.1136/bmjdrc-2022-003036

Figure 2.

Figure 2

Covariate balance between new users of metformin and sulfonylureas using absolute standardized mean differences (SMD) before (unweighted) and after inverse probability of treatment weighting (weighted) for whole cohort (n=112 591). Dotted line indicates SMD cut-off at 0.1 where >0.1 indicates difference in covariates between the metformin and sulfonylurea users. BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HbA1c, hemoglobin A1c.